Hepatocellular carcinoma and liver transplant: beyond the Milan criteria and the risk of "short-blanket" syndrome

作     者：Stefano Gitto Stefano Di Sandro Paolo Magistri Pietro Andreone Fabrizio Di Benedetto Stefano Gitto;Stefano Di Sandro;Paolo Magistri;Pietro Andreone;Fabrizio Di Benedetto

作者机构：Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly Hepato-Pancreato-Biliary Surgery and Liver Transplantation UnitAOU di Modena and University of Modena and Reggio EmiliaModenaItaly Internal and Metabolic MedicineAOU di Modena and University of Modena and Reggio EmiliaModenaItaly 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2020年第9卷第4期

页      面：518-521页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：beyond listed overcome 

摘      要：Liver transplant(LT)is considered the best option for patients with hepatocellular carcinoma(HCC)confined into the liver and generally associated with liver cirrhosis(1).The Milan criteria(MC)represent a milestone in the selection of these patients(2).Therefore,basing on MC,the 5-year survival rate after LT could increase to 70%,with a HCC recurrence rate lower than 10%(2).Despite that,too many patients affected by HCC may not benefit from LT due to a tumor stage beyond the selection *** the last two decades,authors and physicians tried to overcome the MC exploring the opportunity to safely transplant patients beyond(3).Notably,the donor shortage and the competition between patients listed due to HCC and those listed for other indications,force physicians in selecting candidates with the best transplant benefit(3).